Switch theme
Sign up to access all valuation multiples
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
2013
100
Last FY Revenue n/a
LTM EBITDA -$148M
$265M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Solid Biosciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$148M.
In the most recent fiscal year, Solid Biosciences achieved revenue of n/a and an EBITDA of -$122M.
Solid Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Solid Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$148M | XXX | -$122M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$149M | XXX | -$130M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$143M | XXX | -$125M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Solid Biosciences's stock price is $7.
Solid Biosciences has current market cap of $548M, and EV of $265M.
See Solid Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $265M | $548M | XXX | XXX | XXX | XXX | $-2.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Solid Biosciences has market cap of $548M and EV of $265M.
Solid Biosciences's trades at n/a EV/Revenue multiple, and -2.2x EV/EBITDA.
Equity research analysts estimate Solid Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Solid Biosciences has a P/E ratio of -3.8x.
See valuation multiples for Solid Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $548M | XXX | $548M | XXX | XXX | XXX |
| EV (current) | $265M | XXX | $265M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.8x | XXX | -2.2x | XXX | XXX | XXX |
| EV/EBIT | -1.8x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.8x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | -2.8x | XXX | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSolid Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Solid Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Solid Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Solid Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Solid Biosciences acquired XXX companies to date.
Last acquisition by Solid Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Solid Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Solid Biosciences founded? | Solid Biosciences was founded in 2013. |
| Where is Solid Biosciences headquartered? | Solid Biosciences is headquartered in United States of America. |
| How many employees does Solid Biosciences have? | As of today, Solid Biosciences has 100 employees. |
| Who is the CEO of Solid Biosciences? | Solid Biosciences's CEO is Mr. Alexander G. Cumbo. |
| Is Solid Biosciences publicy listed? | Yes, Solid Biosciences is a public company listed on NAS. |
| What is the stock symbol of Solid Biosciences? | Solid Biosciences trades under SLDB ticker. |
| When did Solid Biosciences go public? | Solid Biosciences went public in 2018. |
| Who are competitors of Solid Biosciences? | Similar companies to Solid Biosciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Solid Biosciences? | Solid Biosciences's current market cap is $548M |
| Is Solid Biosciences profitable? | Yes, Solid Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Solid Biosciences? | Solid Biosciences's last 12 months EBITDA is -$148M. |
| What is the current EV/EBITDA multiple of Solid Biosciences? | Current EBITDA multiple of Solid Biosciences is -1.8x. |
| What is the current FCF of Solid Biosciences? | Solid Biosciences's last 12 months FCF is -$94.4M. |
| What is the current EV/FCF multiple of Solid Biosciences? | Current FCF multiple of Solid Biosciences is -2.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
